Medibio Begins Phase Two Trial for Sleep Algorithm
Medibio (ASX:MEB) began a phase two trial investigating the accuracy and performance of its algorithm to detect major depressive episodes via an analysis of sleep signals. The trial, which aims to rec
MT NewswiresSep 3, 2023 23:25 ET
Medibio Completes Phase One Depressive Episode Sleep Trial
Medibio (ASX:MEB) completed its phase one study for the use of an artificial intelligence algorithm to diagnose the potential presence of depressive episodes in patients undergoing polysomnography ass
MT NewswiresJul 24, 2023 02:10 ET
US FDA Denies Breakthrough Device Designation for Medibio's Depression Diagnostic Device
Medibio (ASX:MEB) said on Friday that the US Food and Drug Administration decided that the current version of its depression diagnostic device MEB-001 does not meet the criteria as a breakthrough devi
MT NewswiresJul 20, 2023 21:56 ET
No Data
No Data